Infimer Valuation
| INFR Stock | ILA 20,890 15,890 317.80% |
At this time, the firm appears to be overvalued. Infimer retains a regular Real Value of 17195.25 per share. The prevalent price of the firm is 20890.0. Our model calculates the value of Infimer from evaluating the firm fundamentals such as Operating Margin of (9.80) %, shares owned by insiders of 14.32 %, and Return On Asset of -0.33 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Infimer's price fluctuation is out of control at this time. Calculation of the real value of Infimer is based on 3 months time horizon. Increasing Infimer's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Infimer is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Infimer Stock. However, Infimer's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 20890.0 | Real 17195.25 | Hype 20890.0 | Naive 24588.84 |
The real value of Infimer Stock, also known as its intrinsic value, is the underlying worth of Infimer Company, which is reflected in its stock price. It is based on Infimer's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Infimer's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Infimer helps investors to forecast how Infimer stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Infimer more accurately as focusing exclusively on Infimer's fundamentals will not take into account other important factors: Infimer Total Value Analysis
Infimer is currently forecasted to have takeover price of 25.15 M with market capitalization of 17.99 M, debt of 289 K, and cash on hands of 14 K. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Infimer fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.15 M | 17.99 M | 289 K | 14 K |
Infimer Investor Information
About 14.0% of the company shares are held by company insiders. The company recorded a loss per share of 5.3. Infimer last dividend was issued on the 16th of March 2015. The entity had 1:2 split on the 8th of March 2020. Based on the analysis of Infimer's profitability, liquidity, and operating efficiency, Infimer is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Infimer Asset Utilization
One of the ways to look at asset utilization of Infimer is to check how much profit was generated for every dollar of assets it reports. Infimer retains a negative application of resources of -0.33 (percent), losing 0.003287 for each of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each of resources it retains. Simply put, asset utilization of Infimer shows how discouraging it operates for each spent on its resources.Infimer Ownership Allocation
The market capitalization of Infimer is 17.99 Million. Infimer retains 14.32 (percent) of its outstanding shares held by insiders and 10.35 (percent) owned by outside corporations. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Infimer Profitability Analysis
The company reported the revenue of 378 K. Net Loss for the year was (7.99 M) with loss before overhead, payroll, taxes, and interest of (899 K).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Infimer's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Infimer and how it compares across the competition.
About Infimer Valuation
The stock valuation mechanism determines Infimer's current worth on a weekly basis. Our valuation model uses a comparative analysis of Infimer. We calculate exposure to Infimer's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Infimer's related companies.Infimer Ltd develops technology and production processes for converting municipal solid waste. The company was founded in 2013 and is based in Avihayil, Israel. INFIMER operates under Waste Management classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 23700 people.
8 Steps to conduct Infimer's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Infimer's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Infimer's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Infimer's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Infimer's revenue streams: Identify Infimer's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Infimer's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Infimer's growth potential: Evaluate Infimer's management, business model, and growth potential.
- Determine Infimer's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Infimer's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for Infimer Stock analysis
When running Infimer's price analysis, check to measure Infimer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Infimer is operating at the current time. Most of Infimer's value examination focuses on studying past and present price action to predict the probability of Infimer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Infimer's price. Additionally, you may evaluate how the addition of Infimer to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |